Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Moleculin Biotech Completes Phase 1B/2 Clinical Trial Evaluating Annamycin In Combination With Cytarabine For Acute Myeloid Leukemia

Author: Benzinga Newsdesk | August 27, 2025 08:48am

Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8)

Median OS of 2nd Line efficacy evaluable population of 12 months (n=9)

Median OS of Intent to Treat population (1L-7L) of 9 months (n=22)

OS demonstrated by Annamycin in the MB-106 trial is significantly above industry expectations for relapsed AML (4-6 months)

Clinical study report anticipated in Q1 2026

Company continues to execute Part A of the pivotal MIRACLE Phase 3 trial

Posted In: MBRX